Market Place
Sourcing Support
F2G Secures $100M For Olorofim Development And Commercialization
12 Sep 2024 //
GLOBENEWSWIRE
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at TIMM
21 Oct 2023 //
GLOBENEWSWIRE
F2G Receives CRL from FDA for New Drug Application for Olorofim
20 Jun 2023 //
FINANCE YAHOO
F2G Receives CRL from FDA for NDA for Olorofim for The Treatment
19 Jun 2023 //
PRESS RELEASE
F2G Announces FDA Filing Acceptance of NDA for Olorofim
19 Dec 2022 //
GLOBENEWSWIRE
F2G Announces Data from Phase 2b Study for Olorofimat at ID Week 2022
21 Oct 2022 //
GLOBENEWSWIRE
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim
13 Oct 2022 //
GLOBENEWSWIRE
F2G Announces $70 Million Financing for New Antifungal Agent Olorofim
04 Aug 2022 //
PRNEWSWIRE
F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
11 Nov 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.